🔴 BEAM is trading 4% down today on profit-taking after its BEAM-302 data rally

BEAM is trading 4% down at $36.40 as the stock undergoes a pre-market pullback following a sharp rally driven by positive clinical results.

• The recent gains were fueled by positive Phase 1/2 data for BEAM-302, the company's base-editing program for alpha-1 antitrypsin deficiency.
• The current decline appears to be a period of consolidation and profit-taking, occurring alongside a broader risk-off sentiment across major market indices.